Gedatolisib
| CAS No. | 1197160-78-3 | Cat. No. | BCP01986 |
| Name | Gedatolisib | ||
| Synonyms | PKI-587;PKI587;PKI 587;PF 05212384;PF05212384;PF-05212384; | ||
| Formula | C32H41N9O4 | M. Wt | 615.73 |
| Description | Gedatolisib, also known as PKI-587 and PF-05212384, is an agent targeting the phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in the PI3K/mTOR signaling pathway, with potential antineoplastic activity. Upon intravenous administration, PI3K/mTOR kinase inhibitor PKI-587 inhibits both PI3K and mTOR kinases, which may result in apoptosis and growth inhibition of cancer cells overexpressing PI3K/mTOR. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to chemotherapy and radiotherapy; mTOR, a serine/threonine kinase downstream of PI3K, may also be activated independent of PI3K. | ||
| Pathways | Hormone Pathay GPCR/G Protein PI3K/Akt/mTOR | ||
| Targets | PI3K mTOR GPR | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.